ROSSINI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 423
EU - Europa 232
AS - Asia 84
Totale 739
Nazione #
US - Stati Uniti d'America 423
IT - Italia 65
IE - Irlanda 48
SE - Svezia 37
HK - Hong Kong 34
PL - Polonia 31
CN - Cina 25
JO - Giordania 19
DE - Germania 10
CZ - Repubblica Ceca 7
GB - Regno Unito 7
FR - Francia 5
CH - Svizzera 4
FI - Finlandia 4
RU - Federazione Russa 4
BE - Belgio 3
ES - Italia 3
NL - Olanda 3
SG - Singapore 3
VN - Vietnam 2
TH - Thailandia 1
UA - Ucraina 1
Totale 739
Città #
Chandler 52
Fairfield 49
Dublin 47
Ashburn 38
Woodbridge 33
Ann Arbor 31
Warsaw 30
Houston 29
Hong Kong 28
Cambridge 24
Seattle 21
Wilmington 20
Beijing 11
Florence 10
Lawrence 9
Altamura 8
New York 8
Princeton 8
Brno 7
Shanghai 7
Medford 5
Milan 5
Rome 5
Bern 4
Boardman 4
Boston 4
Buffalo 4
Modena 4
Moscow 4
San Diego 4
Trevignano 4
Barcelona 3
Brussels 3
Esslingen am Neckar 3
Helsinki 3
Amsterdam 2
Bari 2
Bologna 2
Dong Ket 2
Kent 2
Lurate Caccivio 2
Nepi 2
Norwalk 2
Paris 2
Parma 2
Redwood City 2
Rieti 2
Singapore 2
Udine 2
Vicopisano 2
West Jordan 2
Bangkok 1
Busto Arsizio 1
Castel San Giovanni 1
Chicago 1
Frankfurt am Main 1
Hillsboro 1
London 1
Lublin 1
Nagold 1
Naples 1
Prescot 1
San Marco dei Cavoti 1
Saronno 1
Zhengzhou 1
Totale 575
Nome #
Liquid chromatographic/electrospray ionization quadrupole/time of flight tandem mass spectrometric study of polyphenolic composition of different Vaccinium berry species and their comparative evaluation 109
Determination of phthalate diesters and monoesters in human milk and infant formula by fat extraction, size-exclusion chromatography clean-up and gas chromatography-mass spectrometry detection 108
Processing of polymer-derived silicon carbide foams and their adsorption capacity for non-steroidal anti-inflammatory drugs 108
Applicability of the direct injection liquid chromatographic tandem mass spectrometric analytical approach to the sub-ng L-1 determination of perfluoro-alkyl acids in waste, surface, ground and drinking water samples 94
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 92
On-line SPE-LC-MS/MS analysis of wide-range polarity pharmaceutical compounds in aqueous matrices: problems and solutions 73
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: The Colon Life nomogram 60
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 39
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 33
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 32
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO 25
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO 1
Totale 774
Categoria #
all - tutte 3.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.225


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020115 10 3 6 10 11 13 13 10 12 11 13 3
2020/2021108 10 6 7 10 2 9 7 8 13 28 3 5
2021/202256 11 2 0 4 1 4 2 2 0 8 5 17
2022/2023260 12 36 8 20 14 40 34 26 43 2 15 10
2023/2024122 7 10 12 8 10 10 6 35 4 9 8 3
2024/202515 15 0 0 0 0 0 0 0 0 0 0 0
Totale 774